Want to see LADX full AI Analyst Report?
LadRx (LADX) AI Stock Analysis
LadRx
(Other OTC:LADX)
LadRx faces significant financial hurdles, with ongoing losses and negative equity highlighting its financial difficulties. The technical indicators suggest a lack of positive momentum, while the negative P/E ratio reflects its unprofitability and lack of income appeal. These factors result in a low overall stock score, underscoring the potential risks for investors.
LadRx (LADX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $5,446
- Dividend Yield
- ―
- Average Volume (3M)
- 1,800
- Price to Earnings (P/E)
- 0.0
- Beta (1Y)
- -2114.03
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 2
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
LadRx Business Overview & Revenue Model
Company Description
LadRx Corporation, a biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors in the United States. The company offers linker activated drug releases (LADR) technology, a platform consists of an organi...
How the Company Makes Money
LadRx makes money primarily through the development and commercialization of its proprietary cancer therapeutics. The company generates revenue through licensing agreements, partnerships with larger pharmaceutical companies, and potential sales of it...
LadRx Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LADX, the sentiment is Negative. The current price of 0.01 is above the 20-day moving average (MA) of 0.01, above the 50-day MA of 0.01, and below the 200-day MA of 0.05, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 27.03 is Positive, neither overbought nor oversold. The STOCH value of is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LADX.
LadRx Risk Analysis
LadRx disclosed 38 risk factors in its most recent earnings report. LadRx reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
0 New RisksLadRx Peers Comparison
Overall Rating
BCAB45Neutral
CLGN44Neutral
NCNA42Neutral
BRTX38Underperform- LADX28Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| BCAB | 45Neutral | $3.50M | -0.07 | 89.25% | ― | -22.73% | 53.53% |
| CLGN | 44Neutral | $7.82M | -0.44 | -215.58% | ― | -86.76% | 16.63% |
| NCNA | 42Neutral | $4.35M | -0.25 | -41.95% | ― | ― | 99.50% |
| BRTX | 38Underperform | $1.93M | -0.06 | -423.84% | ― | -8.47% | 25.62% |
| LADX | 28Underperform | $5,446 | 0.00 | 9999.00% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| LADX | Ladrx Corporation | 0.01 | -0.74 | -98.53% | |
| CLGN | CollPlant Biotechnologies Ltd. | 4.13 | -18.66 | -81.86% | |
| NCNA | Nucana Plc | 1.01 | -2.93 | -74.37% | |
| BRTX | Biorestorative Therapies, Inc. | 1.40 | -28.60 | -95.33% | |
| SILO | Silo Pharma Inc | 1.23 | -6.57 | -84.23% | |
| BCAB | Bioatla, Inc. | 2.10 | -31.12 | -93.68% |
LadRx Corporate Events
LadRx Board Member Joel Caldwell Resigns
NeutralOn April 14, 2025, Joel Caldwell resigned from the board of directors and all related committees of LadRx Corporation, effective April 15, 2025. His resignation was not due to any disagreements with the company’s operations, policies, or practi...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: May 03, 2025